Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

MRK

Merck & Co Inc

May 01 • 04:00PM ET

112.16

+2.98 2.73 %

Healthcare • Drug Manufacturers - General • USA • Mega • NYSE

May 01, 10:02 AMQ1 earnings beat and raised outlook ignite 4% gain.

Peers: PFE AZN-D NVS BMY JNJ AMGN ABBV GSK LLY SNY

| Held by: VTI VOO IVV SCHD SPY VTV XLV VIG VYM VHT

Scroll to Statements

Index	DJIA, S&P 500	P/E	31.57	EPS (ttm)	3.55	Insider Own	0.18%	Shs Outstand	2.47B	Perf Week	0.23%
Market Cap	277.02B	Forward P/E	11.60	EPS next Y	9.67	Insider Trans	-7.42%	Shs Float	2.47B	Perf Month	-7.18%
Enterprise Value	312.92B	PEG	1.87	EPS next Q	2.08	Inst Own	80.61%	Short Float	1.12%	Perf Quarter	1.71%
Income	8.94B	P/S	4.22	EPS this Y	-42.95%	Inst Trans	0.59%	Short Ratio	2.50	Perf Half Y	29.54%
Sales	65.59B	P/B	5.28	EPS next Y	88.76%	ROA	14.37%	Short Interest	27.50M	Perf YTD	6.56%
Book/sh	21.26	P/C	18.86	EPS next 5Y	6.20%	ROE	36.91%	52W High	125.14 -10.37%	Perf Year	34.71%
Cash/sh	5.95	P/FCF	22.41	EPS past 3/5Y	8.43% 21.23%	ROIC	8.91%	52W Low	73.31 52.99%	Perf 3Y	-3.59%
Dividend Est.	3.19 (2.85%)	EV/EBITDA	9.66	Sales past 3/5Y	3.55% 9.34%	Gross Margin	82.91%	Volatility	2.63% 2.50%	Perf 5Y	57.89%
Dividend TTM	3.32 (2.96%)	EV/Sales	4.77	EPS Y/Y TTM	7.89%	Oper. Margin	27.59%	ATR (14)	3.12	Perf 10Y	114.49%
Dividend Ex-Date	Mar 16, 2026	Quick Ratio	1.30	Sales Y/Y TTM	2.84%	Profit Margin	13.62%	RSI (14)	43.03	Recom	1.72
Dividend Gr. 3/5Y	5.42% 5.75%	Current Ratio	1.54	EPS Q/Q	-185.47%	SMA20	-3.38%	Beta	0.20	Target Price	132.13
Payout	45.05%	Debt/Eq	0.96	Sales Q/Q	4.27%	SMA50	-4.57%	Rel Volume	1.08	Prev Close	109.18
Employees	75000	LT Debt/Eq	0.91	Earnings	Apr 30 BMO	SMA200	12.28%	Avg Volume	10.99M	Price	112.16
IPO	Jun 15, 1946	Option/Short	Yes / Yes	EPS/Sales Surpr.	13.15% 2.77%	Trades		Volume	11,912,372	Change	2.73%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-25-26	Initiated	RBC Capital Mkts	Outperform	$142
Feb-20-26	Initiated	Barclays	Overweight	$140
Feb-13-26	Upgrade	Deutsche Bank	Hold → Buy	$150
Jan-08-26	Upgrade	Wolfe Research	Peer Perform → Outperform	$135
Dec-18-25	Upgrade	BMO Capital Markets	Market Perform → Outperform	$130
Nov-24-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$125
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$105
Oct-13-25	Resumed	Citigroup	Neutral	$95
Sep-17-25	Downgrade	Berenberg	Buy → Hold	$90
May-14-25	Downgrade	Citigroup	Buy → Neutral	$84
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$85
Feb-18-25	Downgrade	Deutsche Bank	Buy → Hold	$128 → $105
Feb-10-25	Downgrade	TD Cowen	Buy → Hold	$121 → $100
Jan-08-25	Downgrade	Truist	Buy → Hold	$110
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$136 → $105
Dec-10-24	Resumed	BofA Securities	Buy	$121
Dec-04-24	Upgrade	HSBC Securities	Hold → Buy	$130
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-11-24	Downgrade	Daiwa Securities	Buy → Neutral
Oct-17-24	Initiated	Bernstein	Mkt Perform	$115

Show Previous Ratings

May-01-26 10:50AM	Eli Lilly Stocks Path To 30% Upside (Trefis)
Apr-30-26 03:03PM	Merck Sales Beat As Winrevair Hits $525 Million (GuruFocus.com)
08:41AM	Merck tops Q1 estimates on strong oncology demand; shares rise (InvestorsHub)
08:21AM	Merck still sees compelling outlook for Terns leukemia drug (BioPharma Dive)
07:45AM	Merck Q1 2026 earnings beat estimates on Keytruda sales (Quartz)
07:09AM	Loading…
07:09AM	Merck beats estimates on strong oncology sales; shares up 4% in pre-market trade (Investing.com)
06:39AM	Merck: Q1 Earnings Snapshot (Associated Press)
06:30AM	Merck Posts Narrower-Than-Expected Loss. These Problems Loom Larger Than Keytruda Patent Cliff. (Barrons.com)
06:30AM	Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones (Business Wire)
05:09AM	Apple headlines a bumper slate of earnings (MarketWatch)
04:05AM	Stock Market Today: Dow, S&P 500 and Nasdaq set to decline as oil hits new four-year high on report of possible Iran military action; Alphabet shares jump as Meta falls (MarketWatch)
Apr-28-26 06:45AM	Merck's Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called "Bad" Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke (Business Wire)
Apr-27-26 01:01PM	Sun Pharma Joins the Big Table With Organon Acquisition (Moby)
10:49AM	Week ahead: Big Tech earnings, Fed decision, and an oil crisis set up Wall Street's biggest test of the year (Proactive)
08:09AM	Sun Pharma to acquire Organon in $11.75 billion deal (Quartz)
06:26AM	Loading…
06:26AM	Sun Pharma to acquire Organon for $11.75bn (Hospital Management)
05:22AM	Organon Stock Jumps After Sun Seals Takeover. Why Pharma M&A Is a Hot Play. (Barrons.com)
01:19AM	Sun Pharma to buy US drugmaker Organon for $11.75 billion in India's largest pharma deal (Reuters)
Apr-26-26 09:53PM	India's Sun Pharma to buy US-listed Organon in $11.75 billion deal (Reuters)
Apr-24-26 06:00PM	Merck & Co Inc: A Significant Addition to Eaton Vance Worldwide Health Sciences Fund (GuruFocus.com)
01:09PM	Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma (Barrons.com)
08:00AM	Nasdaq rises on back of Intel surge boosts tech sentiment, but Dow drops (Proactive)
06:45AM	Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc. (Business Wire)
Apr-23-26 01:08PM	The Week Ahead: FOMC Meeting, Big Tech Earnings (Schaeffer's Research)
04:49AM	MSD teams up with Google Cloud on agentic AI transformation (Hospital Management)
Apr-22-26 10:50AM	Merck investing $1 billion in Google Cloud AI partnership (Quartz)
08:57AM	MSD-backed Ray locks in $125m to back eye drug pipeline (Pharmaceutical Technology)
08:00AM	Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation (PR Newswire)
07:57AM	FDA approves MSDs once-daily HIV combo Idvynso (Pharmaceutical Technology)
07:02AM	Merck to partner with Google Cloud on AI initiatives (Reuters)
02:11PM	Loading…
Apr-21-26 02:11PM	FDA Approves Merck's Once-Daily IDVYNSO (doravirine/islatravir) (Business Wire)
10:07AM	The Dow is outpacing the other indexes due to strong earnings from UnitedHealth Group (MarketWatch)
09:39AM	Mercks fast-ascending kidney cancer drug hits a setback (BioPharma Dive)
06:45AM	Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) (Business Wire)
Apr-20-26 06:48AM	FDA Grants Priority Review for KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer (Business Wire)
06:43AM	AACR 2026: Revolutions next prospect, Mercks reveal and a lung cancer battle (BioPharma Dive)
Apr-17-26 07:49AM	European Commission Approves Mercks ENFLONSIA (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season (Business Wire)
04:00AM	Roches DAC investment; Big Pharmas lavish CEO bumps (Pharma Voice)
Apr-14-26 06:00AM	Merck transforms itself through dealmaking as clock ticks on top-selling drug (Financial Times)
05:05AM	How Merck keeps prices for its blockbuster cancer drug sky high (USA TODAY)
Apr-13-26 11:43AM	How Eli Lilly Stock Rises To $2,000 (Trefis)
09:11AM	This Biotech Stock Soars 38%. Pancreatic Cancer Trial Was a Success. (Barrons.com)
07:00AM	Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy (Business Wire)
05:30AM	Big Pharma Is Thinking Small on Deals. That's a Boon for Biotech. (The Wall Street Journal)
Apr-10-26 10:01AM	This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. (Barrons.com)
Apr-07-26 09:00AM	Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc. (Business Wire)
08:28AM	Terns rebuffed a higher bid before selling to Merck (BioPharma Dive)
12:01AM	Neurocrine Scoops Up Hunger-Drug Maker in Latest Multi-Billion-Dollar Pharma Deal (The Daily Upside)
Apr-03-26 01:05PM	Trump Unveils Up to 100% Tariffs on Imported Medicines With Key Exemptions (GuruFocus.com)
Apr-02-26 09:25AM	Lilly Pushes Back on Making Drug Price Deals Permanent (GuruFocus.com)
08:01AM	JNJ Stocks 60% Breakout: Why Wall Street is Torn (Trefis)
06:50AM	Merck KGaA acquires JSR chromatography business (Pharmaceutical Technology)
06:45AM	European Commission Approves KEYTRUDA (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS =1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens (Business Wire)
Apr-01-26 07:00AM	Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30 (Business Wire)
Mar-31-26 09:32AM	Western Digital upgraded, PayPal initiated: Wall Street's top analyst calls (The Fly)
07:45AM	Blackstone closes largest ever private funding investment round at $6.3bn (Pharmaceutical Technology)
04:00AM	Merck strikes deal with antibody discovery startup (BioPharma Dive)
Mar-30-26 11:09AM	Mercks strategic shift: acquires Terns for $6.7bn, targeting dominance in CML (Pharmaceutical Technology)
Mar-29-26 11:45AM	Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (Business Wire)
Mar-27-26 09:46AM	Wix downgraded, TripAdvisor upgraded: Wall Street's top analyst calls (The Fly)
Mar-26-26 08:10AM	Mercks deal for Terns sparks debate over a possible biotech bidding war (BioPharma Dive)
12:01AM	Merck Preps for End of Keytruda Exclusivity with $6.7B Deal for Leukemia Treatment (The Daily Upside)
Mar-25-26 11:53AM	Why Merck Might Have A Fight On Its Hands With Its $6.7 Billion Takeover Of Terns (Investor's Business Daily)
11:49AM	MSD spends $6.7bn to buy Terns Pharmaceuticals in cancer pipeline reinforcement (Pharmaceutical Technology)
11:23AM	Nasdaq bounces as oil price softens as US pushes for Iran talks (Proactive)
11:06AM	Arm stock skyrockets on chip news, On Holding CEO to step down (Yahoo Finance Video)
10:41AM	Merck to acquire Terns Pharmaceuticals for $6.7B (Proactive)
09:39AM	Merck buying Terns in $6.7B deal to bolster its cancer portfolio before key Keytruda patent expires (Associated Press Finance)
07:35AM	Merck makes a big move into new cancer treatments with a $6.7 billion buyout deal (MarketWatch)
07:21AM	Merck to buy oncology firm Terns Pharmaceuticals in $6.7 billion deal (Investing.com)
06:54AM	MSD and Quotient collaborate on IBD drug targets (Hospital Management)
06:49AM	Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns (The Wall Street Journal)
06:45AM	Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML) (Business Wire)
Mar-24-26 07:01AM	Organon: A High Cash Yield Hidden Behind Patent Fatigue (GuruFocus.com)
Mar-22-26 06:20PM	Peter Thiel is betting big on a $2B AI cow collar startup powered by cowgorithms and investors are fighting to get in (Moneywise)
Mar-20-26 05:19PM	Big drugmakers saved at least $5bn on US taxes shifting income overseas (Financial Times)
Mar-19-26 07:30AM	The $3.4 billion lesson Big Pharma needs to learn: its shelved drugs could save millions of patients (Fortune)
Mar-18-26 04:30PM	FDA Approves BRAVECTO QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs (Business Wire)
Mar-17-26 06:50AM	Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL9 and GARDASIL at the EUROGIN International Multidisciplinary HPV Congress 2026 (Business Wire)
Mar-16-26 08:00AM	Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research (Business Wire)
Mar-15-26 05:05PM	Man's dog was riddled with tumors and dying. He used ChatGPT to design a custom cancer vaccine, stunning researchers (Moneywise)
Mar-13-26 04:00AM	Keytrudas reign continues; pharmas megadeal drought (Pharma Voice)
Mar-11-26 07:45AM	These 4 ETFs Generate $6,000 a Year in Monthly Income for Retirement Investors (24/7 Wall St.)
Mar-09-26 05:45PM	Merck (MRK) Rises Higher Than Market: Key Facts (Zacks)
01:42PM	Factbox-Global drugmakers rush to boost US presence as tariff threat looms (Reuters)
09:35AM	Will Weak Gardasil Sales Continue to Weigh on MRK's Top Line in 2026? (Zacks)
Mar-08-26 04:49PM	These 8 drugs could help fight dementia - and they're already on the market (MarketWatch)
09:00AM	This 5-Star ETF Pays Monthly Dividends and Has Never Missed in 19 Years (24/7 Wall St.)
Mar-07-26 08:03PM	Codexis Targets 2026 Inflection as CEO Touts ECO Synthesis Push in RNA Manufacturing at TD Cowen Conf (MarketBeat)
08:49AM	3 Undervalued Names Too Cheap to Ignore (MarketBeat)
Mar-06-26 10:27AM	Google Grabs Attention, But Funds Go Crazy For This 'Pick-And-Shovel' AI Stock (Investor's Business Daily)
02:33AM	Germanys Merck KGaA Expects Currency Headwinds to Weigh on Earnings (The Wall Street Journal)
Mar-05-26 09:07PM	Oil Prices Fall After Latest Spike, Dow Jones Futures Rise; Broadcom, Nvidia In Focus (Investor's Business Daily)
08:30PM	AI-Powered Tempus Inks New Multi-Year Merck Deal (Benzinga)
06:47PM	Atea Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
11:30AM	Merck (MRK) Up 1.7% Since Last Earnings Report: Can It Continue? (Zacks)
10:25AM	Dow slides more than 550 points to set session low (MarketWatch)
09:55AM	Dow Jones opens lower but Nasdaq flat as Broadcom gains (Proactive)
08:45AM	Can Pfizer Reignite Growth Amid COVID Declines and Patent Expirations? (Zacks)
07:48AM	5 of Bank of Americas US1 List Top Picks Also Pay Big Passive Income (24/7 Wall St.)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Guindo Chirfi	EVP, Access, Policy & Comms	Apr 29 '26	Option Exercise	110.03	1,967	216,429	62,582	May 01 06:54 PM
Chattopadhyay Sanat	Exe V-P & Pres. MMD	Apr 29 '26	Option Exercise	110.03	2,597	285,748	16,477	May 01 06:32 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Apr 29 '26	Option Exercise	110.03	2,518	277,056	162,778	May 01 06:20 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Apr 29 '26	Option Exercise	110.03	1,377	151,511	32,395	May 01 05:56 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 29 '26	Option Exercise	110.03	944	103,868	9,156	May 01 05:55 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 30 '26	Option Exercise	110.95	464	51,481	9,296	May 01 05:55 PM
Li Dean Y	Executive VP & President, MRL	Apr 29 '26	Option Exercise	110.03	4,722	519,562	96,757	May 01 05:45 PM
Zachary Jennifer	EVP, General Counsel	Apr 29 '26	Option Exercise	110.03	2,951	324,699	72,351	May 01 05:43 PM
Larson Betty D	EVP, Chief HR Officer	Apr 30 '26	Option Exercise	110.95	11,350	1,259,282	18,917	May 01 05:42 PM
Larson Betty D	EVP, Chief HR Officer	Apr 29 '26	Option Exercise	110.03	2,085	229,413	8,282	May 01 05:42 PM
Litchfield Caroline	EVP & CFO	Apr 29 '26	Option Exercise	110.03	3,935	432,968	94,239	May 01 05:39 PM
Davis Robert M	Chairman, CEO & President	Apr 29 '26	Option Exercise	110.03	13,300	1,463,399	456,902	May 01 05:38 PM
Oosthuizen Johannes Jacobus	EVP, Oncology & Int?l	Apr 29 '26	Option Exercise	110.03	1,377	151,511	22,574	May 01 05:34 PM
Guindo Chirfi	Chief Marketing Officer	Feb 12 '26	Sale	121.46	10,000	1,214,562	60,615	Feb 12 04:02 PM
DEAN LI	Officer	Feb 10 '26	Proposed Sale	117.52	10,235	1,202,844		Feb 10 04:38 PM
Li Dean Y	Executive VP & President, MRL	Feb 10 '26	Sale	117.52	10,235	1,202,844	92,035	Feb 10 04:04 PM
JENNIFER ZACHARY	Officer	Feb 09 '26	Proposed Sale	119.15	121,573	14,485,690		Feb 09 04:57 PM
CHIRFI GUINDO	Officer	Feb 09 '26	Proposed Sale	118.41	20,000	2,368,202		Feb 09 04:55 PM
Guindo Chirfi	Chief Marketing Officer	Feb 09 '26	Sale	118.41	10,000	1,184,101	70,615	Feb 09 04:04 PM
Zachary Jennifer	EVP, General Counsel	Feb 09 '26	Option Exercise	119.15	121,573	14,485,690	125,708	Feb 09 04:01 PM
Zachary Jennifer	EVP, General Counsel	Feb 09 '26	Sale	119.15	121,573	14,485,690	68,916	Feb 09 04:01 PM
RICHARD ROBERT DELUCA JR.	Officer	Feb 06 '26	Proposed Sale	120.92	37,685	4,557,025		Feb 06 04:35 PM
DAVID WILLIAMS	Officer	Feb 06 '26	Proposed Sale	121.91	5,000	609,525		Feb 06 04:33 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Feb 06 '26	Option Exercise	77.62	5,000	388,100	35,838	Feb 06 04:20 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Feb 06 '26	Sale	121.91	5,000	609,525	30,838	Feb 06 04:20 PM
JOHANNES JACOBUS OOSTHUIZEN	Officer	Feb 06 '26	Proposed Sale	121.87	15,000	1,827,992		Feb 06 04:19 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Feb 04 '26	Option Exercise	62.07	4,000	248,280	14,605	Feb 06 04:18 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Feb 04 '26	Sale	119.67	6,400	765,920	8,205	Feb 06 04:18 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 06 '26	Sale	121.87	15,000	1,827,992	21,197	Feb 06 04:15 PM
Litchfield Caroline	EVP & CFO	Feb 04 '26	Option Exercise	53.06	41,997	2,228,361	132,189	Feb 06 04:13 PM
Litchfield Caroline	EVP & CFO	Feb 04 '26	Sale	119.61	41,997	5,023,312	90,192	Feb 06 04:13 PM
Li Dean Y	Executive VP & President, MRL	Feb 04 '26	Option Exercise	56.04	15,087	845,475	117,357	Feb 06 04:12 PM
Li Dean Y	Executive VP & President, MRL	Feb 04 '26	Sale	118.77	15,087	1,791,824	102,270	Feb 06 04:12 PM
Guindo Chirfi	Chief Marketing Officer	Feb 05 '26	Sale	121.88	20,000	2,437,676	80,615	Feb 06 04:10 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Feb 06 '26	Sale	120.92	37,685	4,557,025	160,174	Feb 06 04:08 PM
Davis Robert M	Chairman, CEO & President	Feb 04 '26	Sale	118.04	47,434	5,599,327	443,602	Feb 06 04:05 PM
CHIRFI GUINDO	Officer	Feb 05 '26	Proposed Sale	121.88	20,000	2,437,676		Feb 05 04:25 PM
DALTON SMART	Officer	Feb 04 '26	Proposed Sale	119.67	6,400	765,920		Feb 04 04:38 PM
ROBERT M. DAVIS	Officer	Feb 04 '26	Proposed Sale	118.02	47,434	5,598,137		Feb 04 04:29 PM
DEAN LI	Officer	Feb 04 '26	Proposed Sale	118.77	15,087	1,791,824		Feb 04 04:27 PM
CAROLINE A LITCHFIELD	Officer	Feb 04 '26	Proposed Sale	119.61	41,997	5,023,312		Feb 04 04:26 PM
Downing Cristal N	Chief Comm. & Public Afrs Ofcr	Nov 10 '25	Sale	87.00	7,085	616,395	0	Nov 12 04:01 PM
CRISTAL DOWNING	Officer	Nov 10 '25	Proposed Sale	87.00	7,085	616,395		Nov 10 04:07 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Nov 03 '25	Sale	83.59	8,614	720,040	24,578	Nov 04 04:02 PM
DAVID WILLIAMS	Officer	Nov 03 '25	Proposed Sale	83.59	8,614	720,040		Nov 03 04:09 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Aug 04 '25	Option Exercise	79.29	17,119	1,357,366	41,445	Aug 05 08:46 AM
Guindo Chirfi	Chief Marketing Officer	Aug 04 '25	Option Exercise	79.29	36,903	2,926,039	107,409	Aug 05 08:43 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRK

Merck & Co Inc

Upgrade your Finviz experience